Edgewise Therapeutics, Inc. () Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

940.23 k

Shareholding (Mar 2025)

FII

14.25%

Held by 96 FIIs

DII

29.13%

Held by 34 DIIs

Promoter

34.34%

How big is Edgewise Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Edgewise Therapeutics, Inc. has a market capitalization of $1.524 billion, with net sales of $0.00 million and a net profit of -$146.09 million over the last four quarters. The company reported shareholder's funds of $459.22 million and total assets of $486.82 million as of Dec 24.

What does Edgewise Therapeutics, Inc. do?

22-Jun-2025

Edgewise Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $41 million and a market cap of $1.52 billion. The company has no dividend yield and negative return on equity.

Is Edgewise Therapeutics, Inc. technically bullish or bearish?

05-Nov-2025

As of October 31, 2025, Edgewise Therapeutics, Inc. shows a neutral trend with mixed signals across indicators, having outperformed the S&P 500 recently but significantly underperformed year-to-date and over the past year.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 1,568 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.01

Return on Equity

-25.58%

Price to Book

2.66

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-36 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

62.01%

6 Months

59.77%

1 Year

-25.81%

2 Years

283.04%

3 Years

167.61%

4 Years

58.07%

5 Years

0.0%

Edgewise Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Is Edgewise Therapeutics, Inc. technically bullish or bearish?

As of 31 October 2025, the technical trend for Edgewise Therapeutics, Inc. has changed from mildly bearish to sideways. The current stance is neutral, with mixed signals across various indicators. The weekly MACD is mildly bullish, while the monthly MACD is mildly bearish. The Bollinger Bands show a mildly bullish trend on the weekly chart but bearish on the monthly. Daily moving averages indicate a mildly bearish position. The KST is bullish weekly but mildly bearish monthly, and there are no discernible trends in Dow Theory or OBV. In terms of performance, the stock has outperformed the S&P 500 over the past week and month, returning 8.08% and 10.7% respectively, while the S&P 500 returned 0.71% and 1.92%. However, year-to-date and one-year returns are significantly negative at -35.11% and -49.04%, compared to the S&P 500's positive returns of 16.30% and 19.89%....

Is Edgewise Therapeutics, Inc. technically bullish or bearish?

As of 31 October 2025, the technical trend for Edgewise Therapeutics, Inc. has changed from mildly bearish to sideways. The current stance is neutral, with mixed signals across different time frames. The weekly MACD is mildly bullish, while the monthly MACD is mildly bearish. The Bollinger Bands indicate a bullish signal on the weekly chart but are mildly bearish on the monthly. Moving averages are showing a mildly bearish trend on the daily timeframe. The KST and Dow Theory are both mildly bullish on the weekly and monthly charts, while the OBV is also mildly bullish across both periods. In terms of performance, the stock has outperformed the S&P 500 over the last week and month, with returns of 12.1% and 14.82% respectively, compared to the S&P 500's 0.71% and 1.92%. However, the year-to-date and one-year returns are significantly negative at -32.7% and -47.15%, respectively, while the S&P 500 has gaine...

Is Edgewise Therapeutics, Inc. technically bullish or bearish?

As of 31 October 2025, the technical trend for Edgewise Therapeutics, Inc. has changed from mildly bearish to sideways. The current stance is neutral, with mixed signals across different time frames. The weekly MACD and KST are mildly bullish, while the monthly MACD and Bollinger Bands are mildly bearish. The daily moving averages indicate a mildly bearish trend. The Dow Theory shows a mildly bullish stance on both weekly and monthly levels. In terms of performance, the stock has outperformed the S&P 500 over the past week and month, with returns of 20.42% and 18.39% respectively, but it has significantly underperformed year-to-date and over the past year, with returns of -31.54% and -45.55%. Overall, the mixed indicators suggest a cautious approach....

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-250.41%

EBIT to Interest (avg)

-106.79

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.01

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.73

EV to EBIT

-6.87

EV to EBITDA

-6.96

EV to Capital Employed

-206.08

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-34.00%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bearish

RSI

Bearish

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Mildly Bearish

Dow Theory

Mildly Bullish

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 52 Schemes (22.28%)

Foreign Institutions

Held by 96 Foreign Institutions (14.25%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -14.60% vs -46.51% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-42.00",
          "val2": "-37.60",
          "chgp": "-11.70%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-36.10",
          "val2": "-31.50",
          "chgp": "-14.60%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -33.53% vs -48.22% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-156.50",
          "val2": "-112.60",
          "chgp": "-38.99%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-133.80",
          "val2": "-100.20",
          "chgp": "-33.53%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-42.00

-37.60

-11.70%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-36.10

-31.50

-14.60%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -14.60% vs -46.51% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-156.50

-112.60

-38.99%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-133.80

-100.20

-33.53%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -33.53% vs -48.22% in Dec 2023

All Annual Results

Company CV

About Edgewise Therapeutics, Inc.

Edgewise Therapeutics, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Edgewise Therapeutics, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Edgewise Therapeutics, Inc.?

Watch in Real-Time

What does Edgewise Therapeutics, Inc. do?

Is Edgewise Therapeutics, Inc. technically bullish or bearish?

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Is Edgewise Therapeutics, Inc. technically bullish or bearish?

Is Edgewise Therapeutics, Inc. technically bullish or bearish?

Is Edgewise Therapeutics, Inc. technically bullish or bearish?

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Edgewise Therapeutics, Inc.

Company Coordinates